Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
摘要:
Pyrimidine analogs of the pyridinylimidazole class of CSBP/p38 kinase inhibitors were prepared in an effort to reduce the potent inhibition of hepatic cytochrome P450 observed for the pyridinyl compounds. The substitution of pyrimidin-4-yl, 2-methoxypyrimidin-4-yl, or 2-methylaminopyrimidin-4-yl for pyridin-4-yl effectively dissociates CSBP/p38 kinctse from P450 inhibition for this series and furthermore achieves an increase in oral activity. (C) 1998 Elsevier Science Ltd. All rights reserved.
[EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
申请人:SERVIER LAB
公开号:WO2015097123A1
公开(公告)日:2015-07-02
Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.
Novel 1, 4, 5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.
1, 4, 5-取代咪唑化合物及其在治疗中作为细胞因子抑制剂使用的组合物。
8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION
申请人:Lu Yingchun
公开号:US20080085898A1
公开(公告)日:2008-04-10
The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:
Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1227091A3
公开(公告)日:2002-08-07
The invention relates to a novel group of formamide compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.
这项发明涉及一类新型的甲酰胺化合物及其制备方法,可用于制备具有多种治疗性能的三取代咪唑。
Imidazole compounds, use and process of making
申请人:——
公开号:US05593991A1
公开(公告)日:1997-01-14
Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.